Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- CarthroniX, Inc.
- Study ID
- NCT07308834
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Osteoarthritis of the Knees
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- CX-011 — DRUGCX-011 is a hydrophobic small molecule for intra-articular (IA) administration that is being developed for the treatment of subjects with osteoarthritis of the knee.
Study Details
Study is designed to evaluate the safety and effectiveness of a drug called CX-011 to treat pain in patients with osteoarthritis of the knee. Osteoarthritis produces pain in the knee (and other joints) that typically is worsened by activities such as long distance walking and is alleviated by rest.
Key Dates
- First listed
- Dec 30, 2025
- Start date
- Aug 11, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 30, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 72 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placebo
- Experimental: CX-011 low dose
- Experimental: CX-011 medium dose
- Experimental: CX-011 high dose
Primary Outcome Measure
Determine tolerability by monitoring the frequency of treatment-emergent adverse events [ Time Frame: 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | Jay Lieberman, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
By research site